Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc/ US4622221004 /
IONS
|
5/17/2024 10:00:00 PM
|
Chg.
-0.3100
|
Volume |
Bid10:02:03 PM |
Ask10:02:03 PM |
High |
Low |
|
37.3100USD
|
-0.82%
|
1.36 mill.
Turnover: 34.21 mill. |
36.5100Bid Size: 1,000 |
41.0000Ask Size: 600 |
37.6550 |
36.5599 |
Business description
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics in the United States. Its portfolio includes SPINRAZA, TEGSEDI, and WAYLIVRA for various genetic disorders. Additionally, it has multiple phase 3 studies underway for treatments addressing conditions like amyotrophic lateral sclerosis and cardiovascular disease. Headquarters: Carlsbad, California. Founded: 1989. Collaborations: Biogen, AstraZeneca, Novartis, and others.
Management board & Supervisory board
| CEO |
| Brett P. Monia |
| Management board |
| Elizabeth L. Hougen, C. Frank Bennett, Onaiza Cadoret-Manier, Joseph T. Baroldi, Richard S. Geary, Patrick R. O’Neil, Eric E. Swayze, Eugene Schneider, Brian Birchler, Michael Yang |
| Supervisory board |
| Joseph Loscalzo, Brett P. Monia, Spencer R. Berthelsen, Allene M. Diaz, Michael Hayden, Joan E. Herman, Joseph Klein, B. Lynne Parshall, Joseph H. Wender |
Company data
| Name: |
Ionis Pharmaceuticals Inc. |
| Address: |
2855 Gazelle Court,Carlsbad, CA 92010 |
| Phone: |
+1-760-931-9200 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.ionispharma.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
99.25% |
| IPO date: |
1/1/1991 |
Investor relations
| Name: |
- |
| IR phone: |
+1-760-603-2331 |
| IR Fax: |
- |
| IR e-mail: |
info@ionisph.com
|
